DEA spokesman Russ Baer confirms the new notice that has alarmed the CBD is primarily an administrative move:
“The gist of the issue is that DEA established a new drug code for marihuana extracts as a means to more accurately reflect the activities of scientific research and provide more consistent adherence to the requirements of the Single Convention.
We have not changed any control status with this Federal Register Notice. Everything remains schedule I, so no other provisions of the law (registration, security requirements, research protocols, etc.) change. Companies will simply use a new code for extracts.”
The ruling allows the DEA to more accurately track elements such as scientific and medical studies, as researchers use the codes to identify which substance they’re examining.
It also recognizes that there is a potential medical benefit to some of the cannabinoids.